Based on a previous multicenter randomized double-blind phase III trial (NCT04487080) for evaluating amivantamab–lazertinib versus osimertinib in EGFR-mutated advanced NSCLC patients (both treatment-naïve and osimertinib-pretreated), we constructed a Markov model for 3-week cycles over a 5-year horizon. Here, EGFR is linked to non-small cell lung carcinoma.